All In MedTech

Device Trial Radar · NCT04743245

Delivery SSO2 Therapy for 60 Min in Anterior MI Patients With PCI ≤ 6 Hours of Symptoms Onset Compared to Standard.

A Post Approval Study to Evaluate the Delivery of Hyperoxemic Super Saturated Oxygen Therapy for 60 Minutes in Anterior AMI Patients Compared to PCI

Last checked: Nov 20, 2026Latest source record: May 29, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Terminated

Status

Terminated

Enrollment

17

Actual

Start

Aug 2, 2022

Primary completion

Apr 10, 2026

Study completion Apr 10, 2026

Sponsor

Lead sponsor
TherOxNot on our public-company list
Sponsor type
Industry
First posted
Feb 8, 2021

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Randomized
Model
Parallel
Masking
Single (outcomes assessor)
Primary purpose
Treatment
FDA-regulated device
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

A multi-center randomized post-approval evaluation of delivery of intracoronary hyperoxemic supersaturated Oxygen therapy for 60 minutes in anterior AMI patients with successful reperfusion (via PCI) within 6 hours after onset of symptoms compared to standard therapy

Conditions

  • Acute Myocardial Infarction
  • STEMI

Interventions

  • TherOx DownStream SystemDevice

    SSO2 Therapy with Therox downstream System after Percutaneous Coronary Intervention (PCI)

  • PCIDevice

    Standard Care of PCI

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. 1-year rate of Net Adverse Clinical Events (NACE)Time frame: 12 months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Baystate Medical Center

    Springfield, Massachusetts

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.